Literature DB >> 18334008

The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology.

D S Chi1, R R Barakat, M J Palayekar, D A Levine, Y Sonoda, K Alektiar, C L Brown, N R Abu-Rustum.   

Abstract

The seminal Gynecologic Oncology Group study on surgical pathologic spread patterns of endometrial cancer demonstrated the risk of pelvic lymph node metastasis for clinical stage I endometrial cancer based on tumor grade and thirds of myometrial invasion. However, the FIGO staging system assigns surgical stage by categorizing depth of myometrial invasion in halves. The objective of this study was to determine the incidence of pelvic lymph node metastasis in endometrial cancer based on tumor grade and myometrial invasion as per the current FIGO staging system. We reviewed the records of all patients who underwent primary surgical staging for clinical stage I endometrial cancer at our institution between May 1993 and November 2005. To make the study cohort as homogeneous as possible, we included only cases of endometrioid histology. We also included only patients who had adequate staging, which was defined as a total hysterectomy with removal of at least eight pelvic lymph nodes. During the study period, 1036 patients underwent primary surgery for endometrial cancer. The study cohort was composed of the 349 patients who met study inclusion criteria. Distribution of tumor grade was as follows: grade 1, 80 (23%); grade 2, 182 (52%); and grade 3, 87 (25%). Overall, 30 patients (9%) had pelvic lymph node metastasis. The incidence of pelvic lymph node metastasis in relation to tumor grade and depth of myometrial invasion (none, inner half, and outer half) was as follows: grade 1-0%, 0%, and 0%, respectively; grade 2-4%, 10%, and 17%, respectively; and grade 3-0%, 7%, and 28%, respectively. We determined the incidence of pelvic nodal metastasis in a large cohort of endometrial cancer patients of uniform histologic subtype in relation to tumor grade and a one-half myometrial invasion cutoff. These data are more applicable to current surgical practice than the previously described one-third myometrial invasion cutoff results.

Entities:  

Mesh:

Year:  2008        PMID: 18334008     DOI: 10.1111/j.1525-1438.2007.00996.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  29 in total

1.  Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer.

Authors:  A Stiekema; Car Lok; C M Korse; W J van Driel; V van der Noort; G G Kenter; K K Van de Vijver
Journal:  Virchows Arch       Date:  2017-04-11       Impact factor: 4.064

Review 2.  Current therapy of patients with endometrial carcinoma. A critical review.

Authors:  S Marnitz; C Köhler
Journal:  Strahlenther Onkol       Date:  2011-12-23       Impact factor: 3.621

3.  Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma?

Authors:  Nadeem R Abu-Rustum; Fady Khoury-Collado; Neeta Pandit-Taskar; Robert A Soslow; Fanny Dao; Yukio Sonoda; Douglas A Levine; Carol L Brown; Dennis S Chi; Richard R Barakat; Mary L Gemignani
Journal:  Gynecol Oncol       Date:  2009-02-20       Impact factor: 5.482

4.  How low is low enough? Evaluation of various risk-assessment models for lymph node metastasis in endometrial cancer: a Korean multicenter study.

Authors:  Sokbom Kang; Jong-Min Lee; Jae-Kwan Lee; Jae Weon Kim; Chi-Heum Cho; Seok-Mo Kim; Sang-Yoon Park; Chan-Yong Park; Ki-Tae Kim
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

5.  A study of pelvic and para-aortic lymph node involvement in surgically staged endometrioid carcinoma of endometrium.

Authors:  Rekha B Raghavendrachar; Julian Crasta; Premalatha T Siddartha; Elizabeth M Vallikad
Journal:  J Obstet Gynaecol India       Date:  2013-04-11

6.  Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion.

Authors:  Christine H Kim; Fady Khoury-Collado; Emma L Barber; Robert A Soslow; Vicky Makker; Mario M Leitao; Yukio Sonoda; Kaled M Alektiar; Richard R Barakat; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2013-10-04       Impact factor: 5.482

7.  Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma.

Authors:  Jennifer J Mueller; Silvana Pedra Nobre; Kenya Braxton; Kaled M Alektiar; Mario M Leitao; Carol Aghajanian; Lora H Ellenson; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2020-04-01       Impact factor: 5.482

8.  Systemic lymphadenectomy cannot be recommended for low-risk corpus cancer.

Authors:  Takao Hidaka; Akitoshi Nakashima; Tomoko Shima; Toru Hasegawa; Shigeru Saito
Journal:  Obstet Gynecol Int       Date:  2010-02-04

9.  Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion.

Authors:  Ane Gerda Zahl Eriksson; Jen Ducie; Narisha Ali; Michaela E McGree; Amy L Weaver; Giorgio Bogani; William A Cliby; Sean C Dowdy; Jamie N Bakkum-Gamez; Nadeem R Abu-Rustum; Andrea Mariani; Mario M Leitao
Journal:  Gynecol Oncol       Date:  2015-12-31       Impact factor: 5.482

10.  Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma.

Authors:  Sami K Saarelainen; Synnöve Staff; Nina Peltonen; Terho Lehtimäki; Jorma Isola; Paula M Kujala; Maarit H Vuento; Johanna U Mäenpää
Journal:  Tumour Biol       Date:  2014-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.